Related Experiment Videos
Corneal neovascularization. Pathogenesis and inhibition.
R J Epstein1, R D Stulting, R L Hendricks
1Department of Ophthalmology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
Cornea
|January 1, 1987
Summary
Corneal neovascularization (CNV) treatment shows promise with photodynamic therapy (PDT). This study explores PDT
Area of Science:
- Ophthalmology
- Immunology
- Vascular Biology
Background:
- Corneal neovascularization (CNV) leads to vision loss and complicates corneal transplants.
- CNV is often triggered by inflammation, involving neutrophils, or specific immune responses like herpes simplex keratitis.
- Immunologically driven CNV may respond better to treatment than inflammation-induced CNV.
Purpose of the Study:
- To investigate the efficacy of photodynamic therapy (PDT) in a murine model of corneal neovascularization (CNV).
- To explore the potential of PDT for treating CNV, particularly immunologically mediated forms.
Main Methods:
- Developed a murine model of CNV using intrastromal injection of stimulated lymphocytes or interleukin-2 (IL-2).
- Administered intravenous hematoporphyrin derivative or dihematoporphyrin ether (DHE) and assessed corneal retention.
- Evaluated the effect of PDT on established CNV in the murine model.
Main Results:
- Corneal retention of DHE was observed in mice with IL-2-induced CNV.
- Preliminary findings suggest PDT can induce regression of CNV in this model.
- The study reviews recent advancements in CNV pathogenesis and treatment.
Conclusions:
- Photodynamic therapy (PDT) shows potential as a treatment for corneal neovascularization (CNV).
- Further research is warranted to optimize PDT protocols and understand its mechanisms in CNV.
- This study contributes to developing novel therapeutic strategies for vision-threatening corneal conditions.